On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

AstraZeneca plans a new investment of $2 billion in the ... Novavax shares fell after the vaccine developer cut its full-year growth projections, offsetting a narrower-than-expected third-quarter loss ...

AstraZeneca said it is in China ‘for the long haul’ and outlined billions of pounds of investment in the US – but a new ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

AstraZeneca's £450 million investment plan for vaccine R&D in the UK is under review as discussions on governmental ...

AstraZeneca has put a £450m investment in Britain under review in a stand-off with ministers over state aid. The drugs giant ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca, the London-listed pharmaceutical company, has put its planned £650 million investment in UK vaccine research and ...

The U.S. vaccine maker now expects between $175 million and $225 ... think tank says 12:09 AM UTC Healthcare & ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...